Bradley Stohr, MD, PhD

Title(s)Professor, Pathology
SchoolSchool of Medicine
Address513 Parnassus Avenue, HSW, #M2380
San Francisco CA 94143
Phone415-476-6729
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoClinical Fellowship

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    The Response of Cancer and Stem/Progenitor Cells to Telomere Disruption
    NIH K08CA134552Jul 15, 2009 - Jun 30, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Dual hyperpolarized [1-13C]pyruvate and [13C]urea magnetic resonance imaging of prostate cancer. Journal of Magnetic Resonance Open. 2024 Dec 1; 21:100165. de Kouchkovsky dI, Nguyen NH, Chen CH, Liu LX, Qin QH, Stohr SB, Santos SR, Ohliger OM, Wang WZ, Bok BR, Gordon GJ, Larson LP, Frost FM, Okamoto OK, Gebrezgiabhier GD, Cooperberg CM, Vigneron VD, Kurhanewicz KJ, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    2. Next-generation sequencing has diagnostic utility in challenging small/flat urothelial lesions. Ann Diagn Pathol. 2024 Aug 19; 73:152370. Pinard A, Chen C, Van Ziffle J, Simko JP, Stohr BA, Chan E. PMID: 39180886.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Wilms Tumor: An Unexpected Diagnosis in Adult Patients. Arch Pathol Lab Med. 2024 Jun 01; 148(6):722-727. Chan GJ, Stohr BA, Osunkoya AO, Croom NA, Cho SJ, Balassanian R, Charu V, Bean GR, Chan E. PMID: 37756569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. Prostate. 2024 Aug; 84(11):1076-1085. Greenland NY, Cooperberg MR, Carroll PR, Cowan JE, Simko JP, Stohr BA, Chan E. PMID: 38734990.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. MP65-18 IDENTIFICATION OF MOLECULAR TARGETS IN BLADDER CANCER VARIANTS USING SINGLE-CELL ANALYSIS. Journal of Urology. 2024 May 1; 211(5S):e1084. Yang YH, Song SH, Allegakoen AP, Lu LK, Yip YE, Hui HK, Chang CK, Kasap KC, Gayle GJ, Stohr SB, Meng MM, Wiita WA, Ding DC, Chou CJ, Porten PS, Huang HF. .
      View in: Publisher Site   Mentions:
    7. Clinicopathologic and Molecular Characterization of High-Risk Human Papillomavirus-Positive Carcinomas of the Urinary Tract. Arch Pathol Lab Med. 2024 Apr 01. Kayraklioglu N, Stohr BA, Chan E. PMID: 38555943.
      View in: PubMed   Mentions:    Fields:    
    8. Abstract 6405: Identification of molecular targets in bladder cancer variants using single-cell analysis. Cancer Research. 2024 Mar 22; 84(6_Supplement):6405-6405. Yang YH, Song SH, Allegakoen AP, Lu LK, Yip YE, Hui HK, Chang CK, Kasap KC, Gayle GJ, Stohr SB, Wiita WA, Ding DC, Meng MM, Chou CJ, Porten PS, Huang HF. .
      View in: Publisher Site   Mentions:
    9. Multicolor fluorescence microscopy for surgical guidance using a chip-scale imager with a low-NA fiber optic plate and a multi-bandpass interference filter. Biomed Opt Express. 2024 Mar 01; 15(3):1761-1776. Roschelle M, Rabbani R, Papageorgiou E, Zhang H, Cooperberg M, Stohr BA, Niknejad A, Anwar M. PMID: 38495694; PMCID: PMC10942699.
      View in: PubMed   Mentions: 1  
    10. Multicolor fluorescence microscopy for surgical guidance using a chip-scale imager with a low-NA fiber optic plate and a multi-bandpass interference filter. bioRxiv. 2024 Feb 04. Roschelle M, Rabbani R, Papageorgiou E, Zhang H, Cooperberg M, Stohr BA, Niknejad A, Anwar M. PMID: 37904924; PMCID: PMC10614810.
      View in: PubMed   Mentions:
    11. Variant subtypes in bladder cancer and CA125-positive cancer cell state. Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):694-694. Yang YH, Song SH, Allegakoen AP, Lu LK, Gayle GJ, Stohr SB, Ding DC, Chou CJ, Meng MM, Porten PS, Huang HF. .
      View in: Publisher Site   Mentions:
    12. Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin. Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):599-599. Shipp SC, Jindal JT, Reyes RK, Zhu ZX, Ding DC, Chan CE, Stohr SB, Deshmukh DP, Fitzgerald FK, Kwon KD, Bose BR, Desai DA, de Kouchkovsky dI, Aggarwal AR, Small SE, Fong FL, Porten PS, Friedlander FT, Chou CJ, Koshkin KV. .
      View in: Publisher Site   Mentions:
    13. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer. Histopathology. 2024 Mar; 84(4):614-623. Greenland NY, Cowan JE, Stohr BA, Simko JP, Carroll PR, Chan E. PMID: 38012532.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2024 Apr; 7(2):222-230. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. PMID: 37474400.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    15. Abstract B066: Genome-wide CRISPR screens identify PTGES3 as a druggable AR modulator. Cancer Research. 2023 Jun 2; 83(11_Supplement):b066-b066. Li LH, Melnyk MJ, Fu FB, Feng FS, Sjöström SM, Shrestha SR, Zhang ZM, Chesner CL, Shin SH, Calvert CM, Chou CJ, Das DR, Egusa EE, Winters WA, Zhu ZJ, Maheshwari MA, Hua HJ, Alshalalfa AM, Chen CW, Stohr SB, Siddiqui SJ, Huang HB, Small SE, Quigley QD, Shokat SK, Gilbert GL, Feng FF. .
      View in: Publisher Site   Mentions:
    16. FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and "NTRK-rearranged" spindle cell neoplasms. Genes Chromosomes Cancer. 2023 11; 62(11):641-647. Warmke LM, Al-Ibraheemi A, Wang L, Parham D, Rudzinski ER, Stohr BA, Miles C, Habeeb O, Davis JL. PMID: 37265193.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells. Hum Pathol. 2023 06; 136:56-62. Bahceci D, Nguyen JK, Sangoi AR, Stohr BA, Chan E. PMID: 36997033.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060; PMCID: PMC10263373.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    19. Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study. Hum Pathol. 2022 11; 129:98-102. Stohr BA, Chan E, Anderson JA, Matoso A, Murati Amador BI, Cheng L, Osunkoya AO. PMID: 36108931; PMCID: PMC10403953.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. PD11-12 ASSOCIATIONS OF SERUM-BASED AND URINE-BASED MOLECULAR DIAGNOSTICS WITH HISTOLOGIC SUBTYPING ON PROSTATE BIOPSY. Investigative Urology. 2022 May 1; 207(Supplement 5):e194. de la Calle dC, Greenland GN, Cowan CJ, Fasulo FV, Maggi MM, Chan CE, Stohr SB, Simko SJ, Shinohara SK, Cooperberg CM, Carroll CP, Nguyen NH. .
      View in: Publisher Site   Mentions:
    21. p53 null phenotype is a "positive result" in urothelial carcinoma in situ. Mod Pathol. 2022 09; 35(9):1287-1292. Sangoi AR, Chan E, Abdulfatah E, Stohr BA, Nguyen J, Trpkov K, Siadat F, Hirsch M, Falzarano S, Udager AM, Kunju LP. PMID: 35322193.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Pathol Res Pract. 2022 Apr; 232:153831. Peng Y, Greenland NY, Lang UE, Stohr BA. PMID: 35287088.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    23. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 7  
    24. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. Am J Surg Pathol. 2022 03 01; 46(3):392-403. Chan E, Stohr BA, Butler RS, Cox RM, Myles JL, Nguyen JK, Przybycin CG, Reynolds JP, Williamson SR, McKenney JK. PMID: 34881751.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. PMID: 35216942; PMCID: PMC10262920.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    26. Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):531-531. Jindal JT, Zhang ZL, Chou CJ, Shui SD, Porten PS, Wong WA, Chan CE, Stohr SB, de Kouchkovsky dI, Borno BH, Bose BR, Kwon KD, Desai DA, Huang HF, Aggarwal AR, Small SE, Fong FL, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    27. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022 01 10; 13(1):141. Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. PMID: 35013146; PMCID: PMC8748675.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    28. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investig Clin Urol. 2022 01; 63(1):27-33. Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. PMID: 34983120; PMCID: PMC8756156.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. Hum Pathol. 2022 01; 119:85-93. Chen CV, Croom NA, Simko JP, Stohr BA, Chan E. PMID: 34800526.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. MP66-08 SINGLE-CELL TRANSCRIPTIONAL PROFILES OF HISTOLOGIC VARIANTS IN BLADDER CANCER. Investigative Urology. 2021 Sep 1; 206(Supplement 3). Yang YH, Song SH, Allegakoen AP, Xie XJ, Lu LK, Stohr SB, Meng MM, Porten PS, Huang HF. .
      View in: Publisher Site   Mentions:
    31. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177; PMCID: PMC8634828.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    32. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors-Initial experience. Cancer. 2021 08 01; 127(15):2693-2704. Tang S, Meng MV, Slater JB, Gordon JW, Vigneron DB, Stohr BA, Larson PEZ, Wang ZJ. PMID: 33844280; PMCID: PMC8565774.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    33. Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):463-463. Chu CC, Sjöström SM, Egusa EE, Gibb GE, Badura BM, Koshkin KV, Stohr SB, Meng MM, Pruthi PR, Friedlander FT, Lotan LY, Black BP, Porten PS, Feng FF, Chou CJ. .
      View in: Publisher Site   Mentions:
    34. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate. 2020 12; 80(16):1421-1428. Greenland NY, Cowan JE, Chan E, Carroll PR, Stohr BA, Simko JP. PMID: 32946625.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. Pathology. 2021 Feb; 53(2):214-219. Anderson JA, Matoso A, Murati Amador BI, Cheng L, Stohr BA, Chan E, Osunkoya AO. PMID: 32951908; PMCID: PMC9281534.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    36. APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. Annals of Oncology. 2020 Sep 1; 31:s593. Natesan ND, Zhang ZL, Martell MH, Devine DP, Stohr SB, Grenert GJ, Van Ziffle VJ, Joseph JN, Bastian BB, Umetsu US, Onodera OC, Chan CE, Desai DA, Porten PS, Chou CJ, Friedlander FT, Fong FL, Small SE, Sweet-Cordero SA, Koshkin KV. .
      View in: Publisher Site   Mentions:
    37. Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Hum Pathol. 2020 08; 102:54-59. Sangoi AR, Chan E, Stohr BA, Kunju LP. PMID: 32673685.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    38. Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e17025-e17025. Natesan ND, Martell MH, Devine DP, Stohr SB, Grenert GJ, Van Ziffle VJ, Joseph JN, Bastian BB, Umetsu US, Onodera OC, Chan CE, Desai DA, Wong WA, Porten PS, Chou CJ, Friedlander FT, Small SE, Fong FL, Sweet-Cordero SE, Koshkin KV. .
      View in: Publisher Site   Mentions:
    39. Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. Pract Lab Med. 2020 Aug; 21:e00164. Lei L, Stohr BA, Berry S, Lockwood CM, Davis JL, Rudzinski ER, Kunder CA. PMID: 32490123; PMCID: PMC7260589.
      View in: PubMed   Mentions: 4  
    40. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. Histopathology. 2020 Jun; 76(7):1084-1090. Chan E, Stohr BA, Croom NA, Cho SJ, Garg K, Troxell ML, Higgins JP, Bean GR. PMID: 32064677.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020 05; 44(5):571-581. Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, Cox RM, Rashid-Kolvear F, Weindel MD, Farkas DH, Trpkov K, McKenney JK. PMID: 31850909.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    42. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Mod Pathol. 2020 09; 33(9):1802-1810. Chan E, Garg K, Stohr BA. PMID: 32313185.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate. 2020 05; 80(8):653-659. Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP. PMID: 32220141.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    44. Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. Cell Stem Cell. 2020 01 02; 26(1):27-33.e4. Chen F, Jimenez RJ, Sharma K, Luu HY, Hsu BY, Ravindranathan A, Stohr BA, Willenbring H. PMID: 31866223; PMCID: PMC8009755.
      View in: PubMed   Mentions: 84     Fields:    Translation:Cells
    45. In Situ Visualization of Telomere Length, Telomere Elongation, and TERT Expression in Single Cells. Curr Protoc Cell Biol. 2019 12; 85(1):e97. Ravindranathan A, Diolaiti ME, Cimini BA, Stohr BA. PMID: 31763768.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    46. Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review. Urology. 2020 Jan; 135:11-19. Fergus KB, Lee AW, Baradaran N, Cohen AJ, Stohr BA, Erickson BA, Mmonu NA, Breyer BN. PMID: 31605681.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    47. TP53 structural variants in metastatic prostatic carcinoma. PLoS One. 2019; 14(6):e0218618. Sirohi D, Devine P, Grenert JP, van Ziffle J, Simko JP, Stohr BA. PMID: 31216325; PMCID: PMC6583940.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    48. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. J Urol. 2019 07; 202(1):90-95. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. PMID: 30810466.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    49. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg Pathol. 2019 04; 43(4):435-445. Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER. PMID: 30585824.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    50. Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance. Journal of Clinical Oncology. 2019 Mar 1; 37(7_suppl):88-88. Zuniga ZK, Washington WS, Simko SJ, Greenland GN, Stohr SB, Cowan CJ, Tenggara TI, Maggi MM, Chan CJ, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    51. Preliminary development of an assay for detection of TERT expression, telomere length, and telomere elongation in single cells. PLoS One. 2018; 13(12):e0206525. Ravindranathan A, Cimini B, Diolaiti ME, Stohr BA. PMID: 30517099; PMCID: PMC6281304.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    52. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018 11; 74(5):668-675. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. PMID: 30181067.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    53. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol. 2018 07; 42(7):927-935. Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. PMID: 29683818.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    54. Abstract 4456: Increased NTF2 levels in melanoma cell lines affect nuclear size and cancer cell characteristics. Molecular and Cellular Biology / Genetics. 2018 Jul 1; 4456-4456. Vukovic VL, Stohr SB, Levy LD. .
      View in: Publisher Site   Mentions:
    55. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study. Mod Pathol. 2018 09; 31(9):1429-1441. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ. PMID: 29765141.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    56. Next-Generation Sequencing Assay Raises New Questions in a Case of Metastatic Prostate Cancer. J Appl Lab Med. 2018 May 01; 2(6):960-964. Abadie JM, Stohr BA. PMID: 33636819.
      View in: PubMed   Mentions:    Fields:    
    57. PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY. The Journal of Urology. 2018 Apr 1; 199(4):e1066. Leapman LM, Nguyen NH, Cowan CJ, Xue XL, Stohr SB, Simko SJ, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    58. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):118-118. Leapman LM, Nguyen NH, Cowan CJ, Xue XL, Stohr SB, Simko SJ, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    59. Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press. Mod Pathol. 2017 10; 30(10):1509-1511. Williamson SR, Grignon DJ, Calió A, Stohr BA, Eble JN, Cheng L. PMID: 28972584.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Abstract 2433: Altering nuclear size impacts cancer cell characteristics in melanoma cell lines. Molecular and Cellular Biology, Genetics. 2017 Jul 1; 2433-2433. Vukovic VL, Stohr SB, Levy LD. .
      View in: Publisher Site   Mentions:
    61. Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):11575-11575. Korn KW, Yey YI, Van Ziffle VJ, Grenert GJ, Joseph JN, Solomon SD, Laurance LM, Talevich TE, Onodera OC, Krings KG, Stohr SB, Blanco BA, Bastian BB. .
      View in: Publisher Site   Mentions:
    62. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2017 05; 71(5):750-759. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. PMID: 27940155.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    63. Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. Mod Pathol. 2017 03; 30(3):407-415. Calió A, Grignon DJ, Stohr BA, Williamson SR, Eble JN, Cheng L. PMID: 27910947.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    64. Abstract 475: NTF2 regulates nuclear size in mammalian cells and may contribute to altered nuclear size in melanoma. Clinical Research (Excluding Clinical Trials). 2016 Jul 15; 475-475. Vukovic VL, Stohr SB, Levy LD. .
      View in: Publisher Site   Mentions:
    65. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol. 2016 09; 29(9):1012-27. Liu SY, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, Hosfield E, Yeh I, Talevich E, Onodera C, Van Ziffle JA, Grenert JP, Bastian BC, Chen YY, Krings G. PMID: 27255162.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    66. Nuclear size is sensitive to NTF2 protein levels in a manner dependent on Ran binding. J Cell Sci. 2016 Mar 15; 129(6):1115-27. Vukovic LD, Jevtic P, Zhang Z, Stohr BA, Levy DL. PMID: 26823604; PMCID: PMC4813295.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    67. Functional Analysis of the Bacteriophage T4 Rad50 Homolog (gp46) Coiled-coil Domain. J Biol Chem. 2015 Sep 25; 290(39):23905-15. Barfoot T, Herdendorf TJ, Behning BR, Stohr BA, Gao Y, Kreuzer KN, Nelson SW. PMID: 26242734; PMCID: PMC4583041.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    68. The Shelterin TIN2 Subunit Mediates Recruitment of Telomerase to Telomeres. PLoS Genet. 2015 Jul; 11(7):e1005410. Frank AK, Tran DC, Qu RW, Stohr BA, Segal DJ, Xu L. PMID: 26230315; PMCID: PMC4521702.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    69. Autophagy-independent senescence and genome instability driven by targeted telomere dysfunction. Autophagy. 2015; 11(3):527-37. Mar FA, Debnath J, Stohr BA. PMID: 25751002; PMCID: PMC4502814.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    70. Abstract 2845: Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody. Clinical Research (Excluding Clinical Trials). 2014 Oct 1; 2845-2845. Deshpande DA, Palencia PS, Bellovin BD, Gemo GA, Giese GT, Stohr SB, Pierce PK, Los LG. .
      View in: Publisher Site   Mentions:
    71. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature. 2014 Aug 14; 512(7513):198-202. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg EC, Le Beau MM, Stohr BA, Méndez J, Morrison CG, Passegué E. PMID: 25079315; PMCID: PMC4456040.
      View in: PubMed   Mentions: 342     Fields:    Translation:AnimalsCells
    72. FPA144, a humanized monoclonal antibody for both FGFR2 -amplified and nonamplified, FGFR2b -overexpressing gastric cancer patients. Journal of Clinical Oncology. 2014 May 20; 32(15_suppl):e15074-e15074. Pierce PK, Deshpande DA, Stohr SB, Gemo GA, Patil PN, Brennan BT, Bellovin BD, Palencia PS, Giese GT, Huang HC, Baker BK, Kavanaugh KW, Hambleton HJ, Los LG. .
      View in: Publisher Site   Mentions:
    73. Coordination and processing of DNA ends during double-strand break repair: the role of the bacteriophage T4 Mre11/Rad50 (MR) complex. Genetics. 2013 Nov; 195(3):739-55. Almond JR, Stohr BA, Panigrahi AK, Albrecht DW, Nelson SW, Kreuzer KN. PMID: 23979587; PMCID: PMC3813861.
      View in: PubMed   Mentions: 6     Fields:    Translation:Cells
    74. In situ visualization of telomere elongation patterns in human cells. Nucleic Acids Res. 2013 Oct; 41(18):e176. Diolaiti ME, Cimini BA, Kageyama R, Charles FA, Stohr BA. PMID: 23963699; PMCID: PMC3794614.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    75. Abstract 2924: The role of autophagy in telomere damage-induced replicative senescence. Molecular and Cellular Biology. 2013 Apr 15; 2924-2924. Charles CF, Debnath DJ, Stohr SB. .
      View in: Publisher Site   Mentions:
    76. The role of telomere biology in cancer. Annu Rev Pathol. 2013 Jan 24; 8:49-78. Xu L, Li S, Stohr BA. PMID: 22934675.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    77. A novel sarcoma with dual differentiation: clinicopathologic and molecular characterization of a combined synovial sarcoma and extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 2012 Jul; 36(7):1093-8. Vergara-Lluri ME, Stohr BA, Puligandla B, Brenholz P, Horvai AE. PMID: 22743288.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    78. The terminal telomeric DNA sequence determines the mechanism of dysfunctional telomere fusion. Mol Cell. 2010 Jul 30; 39(2):307-14. Stohr BA, Xu L, Blackburn EH. PMID: 20670897; PMCID: PMC2920734.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    79. Abstract IA-22: Cellular responses to telomerase perturbations. Oral Presentations - Invited Abstracts. 2009 Dec 1; ia-22-ia-22. Li LS, Matsuguchi MT, Stohr SB, Xu XL, Perry PK, Ren RB, Blackburn BE. .
      View in: Publisher Site   Mentions:
    80. Abstract B64: Telomeric DNA sequence determines the mechanism of dysfunctional telomere fusion in human cancer cells. Poster Presentations - Proffered Abstracts. 2009 Dec 1; b64-b64. Stohr SB, Xu XL, Blackburn BE. .
      View in: Publisher Site   Mentions:
    81. ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. Cancer Res. 2008 Jul 01; 68(13):5309-17. Stohr BA, Blackburn EH. PMID: 18593932; PMCID: PMC2553270.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    82. Coordination of DNA ends during double-strand-break repair in bacteriophage T4. Genetics. 2002 Nov; 162(3):1019-30. Stohr BA, Kreuzer KN. PMID: 12454052; PMCID: PMC1201557.
      View in: PubMed   Mentions: 7     Fields:    Translation:Cells
    83. The tight linkage between DNA replication and double-strand break repair in bacteriophage T4. Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8290-7. George JW, Stohr BA, Tomso DJ, Kreuzer KN. PMID: 11459966; PMCID: PMC37434.
      View in: PubMed   Mentions: 17     Fields:    Translation:Cells
    84. Repair of topoisomerase-mediated DNA damage in bacteriophage T4. Genetics. 2001 May; 158(1):19-28. Stohr BA, Kreuzer KN. PMID: 11333215; PMCID: PMC1461630.
      View in: PubMed   Mentions: 14     Fields:    Translation:Cells
    Bradley's Networks
    Concepts (277)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (73)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.